Depression | | | |
Vilazodone | SERT inhibitor; 5-HT1A agonist | Phase III | Merck |
Lu AA21004 | SERT inhibitor; 5-HT1A agonist; 5-HT3 antagonist | Phase III | H. Lundbeck A/S |
Lu AA24530 | SERT inhibitor; 5-HT2C agonist; 5-HT3 antagonist | Phase III | H. Lundbeck A/S |
Premature ejaculation | | | |
Dapoxetine | SSRI | Launched | Johnson and Johnson |
Schizophrenia | | | |
RG1678 | GLYT1 inhibitor | Phase II | Roche |
Obesity | | | |
Bupropion; naltrexone | NET/DAT inhibitor; opioid receptor antagonist | Phase III | Orexigen |
Bupropion; zonisamide | NET/DAT inhibitor; SERT/DAT inhibitor | Phase II | Orexigen |
Tesofensine | SERT/NET/DAT inhibitor | Phase II | NeuroSearch A/S |
Pain | | | |
Bicifadine | SNRI | Phase II | DOV Pharmaceutical |
Xen2174 | NRI | Phase II | Xenome |